60 CONTACT-01: Efficacy and safety from a phase III study of atezolizumab (atezo) + cabozantinib (cabo) vs docetaxel (doc) monotherapy in patients (pts) with metastatic NSCLC (mNSCLC) previously treated with checkpoint inhibitors and chemotherapy

J. Neal, N. Pavlakis, S-W. Kim, Y. Goto, S.M. Lim, G. Mountzios, E. Fountzilas, A. Mochalova, D.C.C. Christoph, A. Bearz, X. Quantin, R. Palmero, V. Antic, Eun Mi Chun, Tirupathi Rao Edubilli, Yi-Chan Lin, M. Huseni, C. Scheffold, P. Vervaet, T. Newsom-Davis